BAX and non-small cell lung carcinoma: Fisetin (Figure 2) treatment of plasma cancer cells (U266) [103] and human non-small cell lung cancer cell lines (NCI-H460) [32] promoted the activation of caspase-3, upregulated Bax, Bim and Bad proteins expression while down-regulated Mcl-1L and Bcl-2 expression.